Global Schizophrenia Treatments Market Size, Status and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 97

Report ID: 19589

Schizophrenia is a mental disorder characterized by abnormal behavior and failure to understand reality.
The schizophrenia treatment market is expected to witness a high growth over the forecast period owing to the increasing incidence of schizophrenia.
In 2018, the global Schizophrenia Treatments market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Schizophrenia Treatments status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Treatments development in United States, Europe and China.

The key players covered in this study
Johnson and Johnson
Bristol-Myers Squibb
Otsuka
AstraZeneca
Sumitomo Dainippon Pharma
Eli Lilly
Alkermes
Vanda Pharmaceuticals
ALLERGAN
Pfizer

Market segment by Type, the product can be split into
Atypical Antipsychotics
Phenothiazine Antipsychotics
Thioxanthenes
Miscellaneous Antipsychotic Agents

Market segment by Application, split into
Hospital Pharmacies
Drug Stores
Retail Pharmacies
E-Commerce

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Schizophrenia Treatments status, future forecast, growth opportunity, key market and key players.
To present the Schizophrenia Treatments development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Schizophrenia Treatments are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Schizophrenia Treatments Market Size Growth Rate by Type (2014-2025)
1.4.2 Atypical Antipsychotics
1.4.3 Phenothiazine Antipsychotics
1.4.4 Thioxanthenes
1.4.5 Miscellaneous Antipsychotic Agents
1.5 Market by Application
1.5.1 Global Schizophrenia Treatments Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacies
1.5.3 Drug Stores
1.5.4 Retail Pharmacies
1.5.5 E-Commerce
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Schizophrenia Treatments Market Size
2.2 Schizophrenia Treatments Growth Trends by Regions
2.2.1 Schizophrenia Treatments Market Size by Regions (2014-2025)
2.2.2 Schizophrenia Treatments Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Schizophrenia Treatments Market Size by Manufacturers
3.1.1 Global Schizophrenia Treatments Revenue by Manufacturers (2014-2019)
3.1.2 Global Schizophrenia Treatments Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Schizophrenia Treatments Market Concentration Ratio (CR5 and HHI)
3.2 Schizophrenia Treatments Key Players Head office and Area Served
3.3 Key Players Schizophrenia Treatments Product/Solution/Service
3.4 Date of Enter into Schizophrenia Treatments Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Schizophrenia Treatments Market Size by Type (2014-2019)
4.2 Global Schizophrenia Treatments Market Size by Application (2014-2019)

5 United States
5.1 United States Schizophrenia Treatments Market Size (2014-2019)
5.2 Schizophrenia Treatments Key Players in United States
5.3 United States Schizophrenia Treatments Market Size by Type
5.4 United States Schizophrenia Treatments Market Size by Application

6 Europe
6.1 Europe Schizophrenia Treatments Market Size (2014-2019)
6.2 Schizophrenia Treatments Key Players in Europe
6.3 Europe Schizophrenia Treatments Market Size by Type
6.4 Europe Schizophrenia Treatments Market Size by Application

7 China
7.1 China Schizophrenia Treatments Market Size (2014-2019)
7.2 Schizophrenia Treatments Key Players in China
7.3 China Schizophrenia Treatments Market Size by Type
7.4 China Schizophrenia Treatments Market Size by Application

8 Japan
8.1 Japan Schizophrenia Treatments Market Size (2014-2019)
8.2 Schizophrenia Treatments Key Players in Japan
8.3 Japan Schizophrenia Treatments Market Size by Type
8.4 Japan Schizophrenia Treatments Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Schizophrenia Treatments Market Size (2014-2019)
9.2 Schizophrenia Treatments Key Players in Southeast Asia
9.3 Southeast Asia Schizophrenia Treatments Market Size by Type
9.4 Southeast Asia Schizophrenia Treatments Market Size by Application

10 India
10.1 India Schizophrenia Treatments Market Size (2014-2019)
10.2 Schizophrenia Treatments Key Players in India
10.3 India Schizophrenia Treatments Market Size by Type
10.4 India Schizophrenia Treatments Market Size by Application

11 Central & South America
11.1 Central & South America Schizophrenia Treatments Market Size (2014-2019)
11.2 Schizophrenia Treatments Key Players in Central & South America
11.3 Central & South America Schizophrenia Treatments Market Size by Type
11.4 Central & South America Schizophrenia Treatments Market Size by Application

12 International Players Profiles
12.1 Johnson and Johnson
12.1.1 Johnson and Johnson Company Details
12.1.2 Company Description and Business Overview
12.1.3 Schizophrenia Treatments Introduction
12.1.4 Johnson and Johnson Revenue in Schizophrenia Treatments Business (2014-2019)
12.1.5 Johnson and Johnson Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Schizophrenia Treatments Introduction
12.2.4 Bristol-Myers Squibb Revenue in Schizophrenia Treatments Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Otsuka
12.3.1 Otsuka Company Details
12.3.2 Company Description and Business Overview
12.3.3 Schizophrenia Treatments Introduction
12.3.4 Otsuka Revenue in Schizophrenia Treatments Business (2014-2019)
12.3.5 Otsuka Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Company Details
12.4.2 Company Description and Business Overview
12.4.3 Schizophrenia Treatments Introduction
12.4.4 AstraZeneca Revenue in Schizophrenia Treatments Business (2014-2019)
12.4.5 AstraZeneca Recent Development
12.5 Sumitomo Dainippon Pharma
12.5.1 Sumitomo Dainippon Pharma Company Details
12.5.2 Company Description and Business Overview
12.5.3 Schizophrenia Treatments Introduction
12.5.4 Sumitomo Dainippon Pharma Revenue in Schizophrenia Treatments Business (2014-2019)
12.5.5 Sumitomo Dainippon Pharma Recent Development
12.6 Eli Lilly
12.6.1 Eli Lilly Company Details
12.6.2 Company Description and Business Overview
12.6.3 Schizophrenia Treatments Introduction
12.6.4 Eli Lilly Revenue in Schizophrenia Treatments Business (2014-2019)
12.6.5 Eli Lilly Recent Development
12.7 Alkermes
12.7.1 Alkermes Company Details
12.7.2 Company Description and Business Overview
12.7.3 Schizophrenia Treatments Introduction
12.7.4 Alkermes Revenue in Schizophrenia Treatments Business (2014-2019)
12.7.5 Alkermes Recent Development
12.8 Vanda Pharmaceuticals
12.8.1 Vanda Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Schizophrenia Treatments Introduction
12.8.4 Vanda Pharmaceuticals Revenue in Schizophrenia Treatments Business (2014-2019)
12.8.5 Vanda Pharmaceuticals Recent Development
12.9 ALLERGAN
12.9.1 ALLERGAN Company Details
12.9.2 Company Description and Business Overview
12.9.3 Schizophrenia Treatments Introduction
12.9.4 ALLERGAN Revenue in Schizophrenia Treatments Business (2014-2019)
12.9.5 ALLERGAN Recent Development
12.10 Pfizer
12.10.1 Pfizer Company Details
12.10.2 Company Description and Business Overview
12.10.3 Schizophrenia Treatments Introduction
12.10.4 Pfizer Revenue in Schizophrenia Treatments Business (2014-2019)
12.10.5 Pfizer Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details